26U
Curatis Holding AG engages in the acquisition, development, and commercialization of medicines for the prevention, diagnosis, and treatment of rare and specialty care diseases. It offers its products in the areas of fentanyl, breakthrough pain, antiplatelet, metastatic hormone receptor-positive breast cancer, anti-arrhythmic, nasal oil, wilson's disease, cyanide poisoning, digoxin toxicity, antih… Read more
26U (26U) - Net Assets
Latest net assets as of June 2025: €44.56 Million EUR
Based on the latest financial reports, 26U (26U) has net assets worth €44.56 Million EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€54.52 Million) and total liabilities (€9.96 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €44.56 Million |
| % of Total Assets | 81.73% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
26U - Net Assets Trend (2021–2024)
This chart illustrates how 26U's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for 26U (2021–2024)
The table below shows the annual net assets of 26U from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €45.60 Million | +14714.74% |
| 2023-12-31 | €-312.00K | -104.62% |
| 2022-12-31 | €6.75 Million | +1788.25% |
| 2021-12-31 | €-400.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to 26U's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2456400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €72.59 Million | 159.20% |
| Total Equity | €45.60 Million | 100.00% |
26U Competitors by Market Cap
The table below lists competitors of 26U ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Jahwa Electronics Co. Ltd.
KQ:033240
|
$248.39K |
|
ANGLO AMERICAN (NGLB.SG)
STU:NGLB
|
$248.42K |
|
Lipigon Pharmaceuticals AB
ST:LPGO
|
$248.46K |
|
TERADATA
BE:3T4
|
$248.49K |
|
Ellen AB (publ)
ST:ELN
|
$248.28K |
|
YELP-A
BE:Y9L
|
$247.90K |
|
SCE Trust VII
NYSE:SCE-PM
|
$247.85K |
|
Quintegra Solutions Limited
NSE:QUINTEGRA
|
$247.83K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in 26U's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -312,000 to 45,598,000, a change of 45,910,000.
- Net loss of 4,345,000 reduced equity.
- New share issuances of 14,000 increased equity.
- Other factors increased equity by 50,241,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-4.34 Million | -9.53% |
| Share Issuances | €14.00K | +0.03% |
| Other Changes | €50.24 Million | +110.18% |
| Total Change | €- | % |
Book Value vs Market Value Analysis
This analysis compares 26U's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.59x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.91x to 2.59x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | €26.70 | €24.40 | x |
| 2023-12-31 | €-1.07 | €24.40 | x |
| 2024-12-31 | €9.42 | €24.40 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently 26U utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -9.53%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -63.01%
- • Asset Turnover: 0.12x
- • Equity Multiplier: 1.22x
- Recent ROE (-9.53%) is above the historical average (-130.96%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | €-103.00K |
| 2022 | -514.32% | 0.00% | 0.00x | 2.08x | €-35.41 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | €-49.35 Million |
| 2024 | -9.53% | -63.01% | 0.12x | 1.22x | €-8.90 Million |
Industry Comparison
This section compares 26U's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $10,270,781,919
- Average return on equity (ROE) among peers: -45.66%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| 26U (26U) | €44.56 Million | 0.00% | 0.22x | $248.33K |
| 27N0 (27N0) | $11.56 Million | -0.93% | 0.00x | $4.66K |
| China Resources Pharmaceutical Group Limited (640) | $90.18 Billion | 4.60% | 1.68x | $940.63 Million |
| CIG WIRELESS (6CW) | $27.09 Million | -110.19% | 3.19x | $56.65 Million |
| Solasia Pharma K.K (9SO) | $1.16 Billion | -167.91% | 0.18x | $34.42 Million |
| Apontis Pharma AG (APPH) | $3.46 Million | -34.21% | 7.59x | $11.70 Million |
| Akebia Therapeutics Inc (AX9) | $635.93 Million | -22.58% | 0.57x | $283.56 Million |
| Biofrontera AG (B8FK) | $-12.89 Million | 0.00% | 0.00x | $3.86 Million |
| AVALA RES (CVJ) | $91.87 Million | -27.32% | 0.11x | $113.22K |
| Deciphera Pharmaceuticals Inc (D05) | $341.69 Million | -52.37% | 0.33x | $2.11 Billion |